You are here: Home » Companies » News
Business Standard

Lupin to review US lawsuit accusing it of price fixing, customer allocation

The company faces charges along with other companies such as Sun Pharma, Dr Reddy's Laboratories and Wockhardt

Press Trust of India  |  New Delhi 

Lupin | File Photo

Drug maker Lupin said on Wednesday that it is reviewing the details of a filed in a court accusing 21 generic medicine producers of hatching a conspiracy to fix prices.

"We have received a copy of the filed gainst the generic drug manufacturers and are reviewing details of the same," Lupin Ltd said in a regulatory filing.

"The company has been a key pharmaceutical player in the and has demonstrated full commitment to compliance with all laws and ethical business practices," it added.

The Mumbai-based drug firm along with various other domestic like Sun Pharma, Dr Reddy's Laboratories and are among the 21 generic pharmaceutical firms and 15 other individual defendants against whom the Attorneys General of 49 states, the Commonwealth of Puerto Rico and the District of Columbia had filed a complaint with respect to 116 generic in the US District Court for the District of Connecticut.

The have been accused of violating antitrust laws by fixing prices and allocating customers.

Lupin shares were trading 3.66 per cent down at Rs 779.50 apiece on the BSE.

First Published: Wed, May 15 2019. 15:36 IST